Epilepsy is the most common neurological disorder in dogs, affecting an estimated 1–5% of the dog population. While seizures themselves are acute welfare events, the chronic nature of epilepsy and the effects of ongoing medication create long-term welfare considerations that require systematic management.
Generalised tonic-clonic seizures involve loss of consciousness, violent muscular activity, paddling, salivation, and often urination and defaecation. The ictal phase (active seizure) typically lasts 1–3 minutes. The post-ictal phase — disorientation, anxiety, temporary blindness, extreme hunger and thirst — may last minutes to hours and is itself a welfare concern. Multiple seizures in 24 hours (cluster seizures) or a seizure lasting more than 5 minutes (status epilepticus) are life-threatening emergencies requiring immediate veterinary treatment.
Current epilepsy management guidelines recommend initiating antiepileptic drug (AED) therapy when: the inter-seizure interval is less than 4–6 weeks, the dog has experienced cluster seizures or status epilepticus, or post-ictal signs are severe or prolonged. These thresholds reflect the welfare impact of frequent seizures rather than the seizure frequency alone. Dogs experiencing monthly or more frequent seizures have measurable welfare impacts between seizures — caregiver anxiety, owner vigilance fatigue, and reduced household normalcy all affect quality of life.
First-line AEDs for dogs include phenobarbital and imepitoin (both licensed), and potassium bromide as an adjunct. Each has welfare implications: phenobarbital causes sedation (particularly initially), increased appetite and thirst, and with long-term use, hepatotoxicity requiring regular monitoring. Imepitoin has a better side effect profile but less efficacy in some dogs. Levetiracetam, pregabalin, and zonisamide are second-line options with different profiles. Balancing seizure control with medication side effects is the central management challenge.
Validated quality of life instruments for epileptic dogs assess: seizure frequency and severity, medication side effects, post-ictal duration and severity, impact on normal activities (exercise, play, interaction), owner anxiety and burden, and behavioural changes between seizures. The EVET (Liverpool Seizure Severity Scale for dogs) and client-reported quality of life questionnaires provide structured assessment tools. Regular QoL assessment guides medication adjustment decisions.
Owners of epileptic dogs experience significant psychological burden — anxiety about witnessing seizures, fear of status epilepticus, and the emotional impact of managing a chronic disease. Psychosocial support, clear emergency protocols, and realistic management expectations from veterinary teams improve both owner wellbeing and adherence to treatment plans. The welfare of the dog and the owner are interconnected — supporting both improves outcomes for both.
← Back to Animal Welfare Hub